Skip to main content

Table 2 Female and male gametocyte prevalence and density

From: Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment

 

Pyronaridine–artesunate

Artemether–lumefantrine

P value*

Pfs25 QT-NASBA prevalence, % (no./No.)

 Day 0

95.3 (81/85)

94.7 (71/75)

1.000

 Day 3

37.0 (30/81)

31.0 (22/71)

0.433

 Day 7

21.7 (18/83)

16.7 (12/72)

0.430

 Day 14

15.2 (12/79)

7.58 (5/66)

0.156

Pfs25 QT-NASBA density, median (IQR)a

 Day 0

3.23 (0.68–18.1)

6.36 (1.19–22.2)

0.229

 Day 3

3.86 (0.33–16.4)

3.73 (0.33–6.91)

0.630

 Day 7

2.82 (1.17–33.5)

0.74 (0.23–12.9)

0.150

 Day 14

6.19 (2.10–27.2)

1.45 (0.65–1.69)

0.092

Pfs25 qRT-PCR prevalence, % (no./No.)

 Day 0

97.7 (83/85)

100 (75/75)

0.499

 Day 3

30.9 (25/81)

33.8 (24/71)

0.699

 Day 7

19.3 (16/83)

16.7 (12/72)

0.674

 Day 14

13.9 (11/79)

6.06 (4/66)

0.122

Pfs25 qRT-PCR density, median (IQR)a

 Day 0

2.88 (0.85–5.24)

1.94 (0.77–5.35)

0.568

 Day 3

0.58 (0.30–1.66)

0.30 (0.14–0.62)

0.039

 Day 7

0.78 (0.33–15.5)

0.28 (0.16–0.83)

0.126

 Day 14

0.33 (0.14–6.42)

0.12 (0.08–0.90)

0.322

PfMGET qRT-PCR prevalence (%) (no./No.)

 Day 0

35.3 (30/85)

41.3 (31/75)

0.433

 Day 3

34.6 (28/81)

36.6 (26/71)

0.792

 Day 7

31.3 (26/83)

30.6 (22/72)

0.918

 Day 14

22.8 (18/79)

19.7 (13/66)

0.652

PfMGET qRT-PCR density, median (IQR)b

 Day 0

0.94 (0.11–14.1)

0.48 (0.21–10.1)

0.920

 Day 3

2.55 (0.21–11.0)

0.82 (0.17–5.07)

0.341

 Day 7

3.23 (0.21–8.95)

1.22 (0.19–11.5)

0.551

 Day 14

1.81 (0.30–11.2)

1.51 (0.66–6.91)

0.779

Total qRT-PCR prevalence, % (no./No.)

 Day 0

97.7 (83/85)

100 (75/75)

0.499

 Day 3

42.0 (34/81)

43.7 (31/71)

0.841

 Day 7

32.5 (27/83)

31.9 (23/72)

0.920

 Day 14

25.3 (20/79)

21.2 (14/66)

0.560

Total qRT-PCR density, median (IQR)c

 Day 0

3.23 (0.86–7.54)

2.24 (0.91–6.13)

0.642

 Day 3

1.20 (0.24–11.0)

1.06 (0.11–5.21)

0.248

 Day 7

3.47 (0.26–15.5)

1.69 (0.27–12.3)

0.631

 Day 14

1.66 (0.30–14.6)

1.34 (0.55–7.00)

0.662

  1. * P-values represent between group differences. Prevalence differences were tested with the Chi squared or Fisher’s Exact test. Differences in gametocyte density were tested with the Wilcoxon rank-sum test
  2. Data included: a female gametocyte positive individuals, b male gametocyte positive individuals, c male and/or female gametocyte positive individuals